ScripThe ultra-rare disease specialist Ultragenyx is approaching several important catalysts this year, including US Food and Drug Administration action on UX111 – the firm’s first gene therapy, which targ
Pink SheetOne-third of all the regenerative medicine advanced therapy (RMAT) designations granted by the US Food and Drug Administration’s Center for Biologics Evaluation and Research were awarded in fiscal yea
ScripAstellas Is Looking For Bolt-On Deals Astellas Pharma is looking to add new assets to its pipeline that could launch in the late 2020s or early in the next decade, chief strategy officer Adam Pearson
ScripIonis has brought products to market under partnerships – namely Biogen’s spinal muscular atrophy drug Spinraza (nusinersen) and the recently launched transthyretin amyloidosis drug Wainua (eplonterse